Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Sponsor: Addex Pharma S.A.
Terminated
Terminated prior to completing enrollment goals due to COVID-related difficulties in recruiting patients
Other terminated trials from Addex Pharma S.A.
More terminations from Addex Pharma S.A.
Other Dyskinesia, Drug-Induced trials with similar outcome
Listed as NCT04857359, this PHASE2/PHASE3 trial focuses on Dyskinesia, Drug-Induced and Dyskinesias and remains terminated or withdrawn. Sponsored by Addex Pharma S.A., it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Unknown → Terminated
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jun 2022 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
Mar 2022 — Jun 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Addex Pharma S.A.
For direct contact, visit the study record on ClinicalTrials.gov .